Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 6/20 | 0.51 |
| ▸ | CNR2 | P34972 | 4/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | KDM6B | O15054 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CISD1 | Q9NZ45 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748664 | 0.98 | CNR2 (0.50) | PLK1CNR2CNR1KDM6BKDM4C | |
| SCHEMBL27756887 | 0.88 | PLK1 (0.52) | PLK1CNR2CNR1KDM6BKDM4C | |
| SCHEMBL2382976 | 0.87 | CNR2 (0.50) | PLK1CNR2CNR1KDM6BKDM4C | |
| SCHEMBL5694119 | 0.86 | PLK1 (0.66) | PLK1CNR2CNR1KDM6BKDM4C | |
| SCHEMBL11432358 | 0.86 | PLK1 (0.66) | PLK1CNR2CNR1KDM6BKDM4C | |
| SCHEMBL11437269 | 0.86 | PLK1 (0.66) | PLK1CNR2CNR1KDM6BKDM4C | |
| SCHEMBL5272720 | 0.86 | PLK1 (0.66) | PLK1CNR2CNR1KDM6BKDM4C | |
| SCHEMBL11443814 | 0.86 | PLK1 (0.66) | PLK1CNR2CNR1KDM6BKDM4C | |
| SCHEMBL11430175 | 0.86 | PLK1 (0.66) | PLK1CNR2CNR1KDM6BKDM4C | |
| SCHEMBL3475665 | 0.86 | PLK1 (0.66) | PLK1CNR2CNR1KDM6BKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |